Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned an average rating of “Hold” from the six brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $2.00.

ARWR has been the topic of several research analyst reports. Piper Jaffray Companies reissued a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Jefferies Group LLC reissued a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 24th. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price objective (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. Finally, Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th.

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its stake in shares of Arrowhead Pharmaceuticals by 3.7% during the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after purchasing an additional 11,099 shares during the period. Wells Fargo & Company MN raised its stake in shares of Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 88,933 shares during the period. LMR Partners LLP bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $467,000. SG Americas Securities LLC raised its stake in shares of Arrowhead Pharmaceuticals by 287.9% during the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 74,776 shares during the period. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 414.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 53,500 shares during the period. Institutional investors own 20.62% of the company’s stock.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The business had revenue of $9.34 million for the quarter, compared to analysts’ expectations of $5.29 million.

ILLEGAL ACTIVITY WARNING: “Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Rating of “Hold” from Brokerages” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/02/arrowhead-pharmaceuticals-inc-arwr-receives-consensus-rating-of-hold-from-brokerages.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.